Drug intelligence / Profile preview

CU-104

Development stage: Phase 2
Lead developer: Curacle
Modality: Small Molecules
Administration: Oral

Overview

CU-104 is an oral small molecule drug being developed by Curacle for the treatment of ulcerative colitis. It is classified as an anti-inflammatory agent and is reported to act as an inhibitor of interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha. The drug is a new molecular entity and has reached Phase 2 clinical trials for moderate to severe ulcerative colitis. No brand names or approved indications are currently associated with this compound.

Targets

IL1B (Interleukin-1 beta)TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)

Beyond the preview

Go deeper on CU-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CU-104.

Explore the full profile